A study of the binding energies of efavirenz to wild-type and K103N/Y181C HIV-1 reverse transcriptase based on the ONIOM method

被引:16
作者
Srivab, Pensri [1 ]
Hannongbua, Supa [1 ,2 ,3 ]
机构
[1] Kasetsart Univ, Fac Sci, Dept Chem, Bangkok 10900, Thailand
[2] Kasetsart Univ, Ctr Nanotechnol, Bangkok 10900, Thailand
[3] Kasetsart Univ, NANOTEC Ctr Excellence, Bangkok 10900, Thailand
关键词
binding energy; HIV-1; RT; inhibitor-enzyme interactions; NNRTIs; ONIOM;
D O I
10.1002/cmdc.200700181
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A three-layered ONIOM model was used to study the interactions between efavirenz and the binding sites of HIV-1 reverse transcriptase (RT): wild-type and double mutant K103N/Y181C enzyme forms. Binding energies were determined and compared to describe the loss of activity of efavirenz with the mutant HIV-1 RT binding pocket. The calculated binding energy for the efavirenz-K103N/Y181C HIV-1 RT complex is less than that with the wild-type-complex by approximately 8 kcal mol(-1). The interaction energies, calculated at the MP2/6-31G(d,p) level between efavirenz and individual residues surrounding the binding pocket of the K103N/Y181C enzyme, demonstrate that the attractive interactions between efavirenz and residue positions 107 and 103 were less than those for wild-type RT by 5.52 and 3.62 kcal mol(-1), respectively. Understanding these interactions could be useful in the design of inhibitors specific for the HIV-1 RT allosteric site and that have greater potency against the mutant enzyme.
引用
收藏
页码:803 / 811
页数:9
相关论文
共 50 条
  • [1] TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1
    Andries, K
    Azijn, H
    Thielemans, T
    Ludovici, D
    Kukla, M
    Heeres, J
    Janssen, P
    De Corte, B
    Vingerhoets, J
    Pauwels, R
    de Béthune, MP
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (12) : 4680 - 4686
  • [2] CALCULATION OF SMALL MOLECULAR INTERACTIONS BY DIFFERENCES OF SEPARATE TOTAL ENERGIES - SOME PROCEDURES WITH REDUCED ERRORS
    BOYS, SF
    BERNARDI, F
    [J]. MOLECULAR PHYSICS, 1970, 19 (04) : 553 - &
  • [3] Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: Past, present, and future perspectives
    Campiani, G
    Ramunno, A
    Maga, G
    Nacci, V
    Fattorusso, C
    Catalanotti, B
    Morelli, E
    Novellino, E
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (08) : 615 - 657
  • [4] Dapprich S., 1999, J. Mol. Struct, V21, P461
  • [5] Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants
    Das, K
    Clark, AD
    Lewi, PJ
    Heeres, J
    de Jonge, MR
    Koymans, LMH
    Vinkers, HM
    Daeyaert, F
    Ludovici, DW
    Kukla, MJ
    De Corte, B
    Kavash, RW
    Ho, CY
    Ye, H
    Lichtenstein, MA
    Andries, K
    Pauwels, R
    de Béthune, MP
    Boyer, PL
    Clark, P
    Hughes, SH
    Janssen, PAJ
    Arnold, E
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (10) : 2550 - 2560
  • [6] Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097
    Das, Kalyan
    Sarafianos, Stefan G.
    Clark, Arthur D., Jr.
    Boyer, Paul L.
    Hughes, Stephen H.
    Arnold, Eddy
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2007, 365 (01) : 77 - 89
  • [7] DELCLERCQ E, 1999, FARMACO, V54, P26
  • [8] DELCLERCQ E, 2004, J CLIN VIROL, V30, P115
  • [9] Frisch M.J., 2004, Gaussian 03
  • [10] Revision C.02